Natera anticipates 2023 total revenue of $980 million to $1.0 billion; 2023 gross margin to be approximately 41% to 44% of revenues; selling, general and administrative costs to be approximately $510 million to $540 million; research and development costs to be $325 million to $345 million, and net cash consumption to be $300 million to $325 million.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NTRA:
- Personalis price target lowered to $5 from $11 at Morgan Stanley
- Natera price target raised to $80 from $70 at Piper Sandler
- New paper highlights clinical utility of Natera’s Renasight in kidney disease
- Raymond James Sees ‘Multiple Expansion’ to Drive Stock Market Returns — Here Are 2 Stocks to Play That Bullish Sentiment
- Natera announces new data on MRD test to be presented at ASCO GI 2023
